Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
4
×
boston blog main
clinical trials
life sciences
national blog main
boston
boston top stories
national top stories
new york blog main
rna interference
san francisco blog main
alexion pharmaceuticals
alirocumab
alnylam pharmaceutials
alnylam pharmaceuticals
amgen
arrowhead pharmaceuticals
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
bluebird bio
boehringer ingelheim
deals
dicerna pharmaceuticals
drugs
duchenne muscular dystrophy
dyne therapeutics
eli lilly
evercore isi
evolocumab
facioscapulohumeral muscular dystrophy
gene therapy
heart attack
hepatitis b
inclisiran
indiana blog main
indiana top stories
johnson & johnson
joseph swartz
What
long
4
×
medicines
4
×
ago
based
data
drug
rna
abandoning
alderley
alnylam
amadeus
baggage
biotech
biotechs
capital
catapult
centre
cheshire
chief
cholesterol
commercial
companies
considering
cuts
deal
development
dicerna
discovery
diseases
dyne
early
evidence
expected
experimental
eyes
free
genetic
gets
having
heart
Language
unset
Current search:
biotech
×
long
×
medicines
×
@tech.eu
1 year ago
Amadeus Capital Partners’ Volker Hirsch joins Medicines Discovery Catapult as Chief Commercial Officer
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
